NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch » TOP China Pharmas  1  2  3  4  5  6  » 
found files: 106
3SBIO (Shenyang Sunshine) »03/05/2007 [Company watch]
3SBio Inc. Announces First Quarter 2007 Results

this company is getting a lot of attention - sells products similar to Amgen but without the side effects. Very large growth potential...   more»


SinoBiomed »10/05/2007 [Company watch]
SinoBiomed facility gets GMP certification from SFDA

Chinese State Food and Drug Administration (SFDA) has recertified Shanghai Wanxing Bio-pharmaceuticals’ recombinant human interferon production plant as a Good Manufacturing Practice (GMP) facility. Shanghai Wanxing Bio-pharmaceuticals is a 82 percent owned subsidiary of China-based SinoBiomed. The 2,500 sq mt plant passed the local GMP re-certification inspection that the SFDA conducted from April 12 to 14, 2007 in Shanghai. The facility produces recombinant human interferon powder for injection. Recombinant human interferon is widely used for treating chronic hepatitis B, hepatitis C, a number of viral infections, and tumors. In meeting Chinese national drug GMP certification standards, the plant's heating ventilation air conditioning system achieved a grade of 100 in the SFDA’s air cleanliness classification, equivalent to a B grade in the US air cleanliness classification. The facility has one of China's largest production capacities and has produced some 12 million doses of recombinant human interferon since its initial five-year certification on December 12, 2001. The recertification authorizes production for another five-year term, ensuring quality control for the product as Shanghai Wanxing expands national and international distribution....   more»


China Biopharmaceuticals Holdings »10/05/2007 [Company watch]
China Biopharmaceuticals Holdings (CHBP) has named new officers and directors for its organization

The company has named Ms Zhang Jian as Chairwoman of the Board of Directors, Mr Shi Mingsheng as Chief Operating Officer and Mr Ding Weihua as member of the Board of Directors. The appointments come into effect from April 30, 2007. Ms Zhang Jian served as the General Manager of Suzhou Erye Pharmaceutical Company Limited (Erye) since 2003. Prior to being the General Manager for Erye, she served for more than five years as the deputy general manager of Suzhou Pharmaceutical Company. Ms Zhang has extensive background and experience in the pharmaceuticals industry having worked in various managerial positions and various aspects of the industry. She is known to be an expert in managing the growth of the company. In her new position, she will be overseeing the company's strategic growth and handle all responsibilities of the company’s operations. Mr Shi Mingsheng, named as the Chief Operating Officer of CHBP, previously served as the chairman of Suzhou Erye Pharmaceutical Company Limited since 2003. In association with Ms Zhang Jian, he built a profitable business, which currently has a joint venture with China Biopharmaceuticals. Mr Ding Weihua, elected to the Board of Directors of the company, is a veteran in the pharmaceuticals industry having worked in the field for more than 33 years. Mr Ding worked for nine years as deputy general manager and manager in sales and marketing at Erye. Prior to his positions in Erye, he worked for six years in business planning at Jiangsu Nantong Qinfen Pharmaceutical Company. “These new appointments not only add depth to our management team but demonstrate our commitment to enhancing our corporate governance. The experience that all three members bring from our most successful subsidiary to date, Eyre, will have an immediate positive impact on the management and performance of China Biopharmaceuticals,” said Mr Chris Peng Mao, Chief Executive Officer of China Biopharmaceuticals....   more»


TOP NEWS
Hutchinson Meditech
»20/06/2007 [Company watch]
Meditech Pays $3.3 Million for R&D Facility

Building in Zhang Jiang High-Tech Park in Shanghai Hutchinson MediPharma Ltd., a division of Hutchinson China Meditech Ltd. (London: HCM) (see story), purchased for $3.3 million the R&D facility in Shanghai it currently occupies....   more»


China Sky One Medical,Inc. »05/07/2007 [Company watch]
China Sky One Medical Passes Recent SFDA Inspection

China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that its facilities and products passed a surprise inspection by China State Food and Drug Administration (SFDA) on June 28, 2007. Government officials and industry professionals working for the SFDA inspected the Company\\\\\\\'s production process, including the quality of raw materials, final packaging, consumer instructions, as well as stock-keeping methods...   more»


3SBIO (Shenyang Sunshine) »15/08/2007 [Company watch]
3SBio Hits Q2 Targets, Reports 50% Increase in Revenue

3SBio (SSRX), the Shenyang biotech that made its U.S. IPO in February, released its second quarter financial report, showing the company greatly increased both revenues and earnings....   more»


Lotus Pharmaceuticals »21/08/2007 [Company watch]
Lotus Pharmaceuticals, Reports $21 Million in Revenues and $4.1 Million in Net Profits in Quarterly Filing

Lotus Pharmaceuticals, Inc. released its second quarter results, with revenues topping $21 million, net profits of $4.1 million, and net assets of $17 million. r. Adam Wasserman, Lotus Chief Financial Officer, reported: ``Total revenues for the six months ended June 30, 2007 were $21,095,000 as compared to total revenues of $16,047,000 for the six months ended June 30, 2006, an increase of $5,048,000 or approximately 31.5%. Lotus' working capital position increased $4,783,000 to $13,429,000 at June 30, 2007 from $8,646,000 at December 31, 2006.'' Dr. Shaohua Tan, Genesis Director in Beijing, observed: ``Lotus seems to go from strength-to-strength. Just six weeks ago, Gold Horse International joined Lotus as a graduate from our private-to-public program. We are hopeful that a third Chinese partner company, prominent in environmental technologies, will join these alumni as a new U.S. public company before the end of Genesis' current fiscal year.''...   more»


3SBIO (Shenyang Sunshine) »03/11/2007 [Company watch]
3SBio takes lion share in China's EPO market

Recombinant human erythropoietin (EPO) injection product Epiao of Shenyang Sunshine Pharmaceutical Co., Ltd. (3Sbio, SSRX.NASDAQ) has seen brisk sales and now takes a market share of 37 percent in China....   more»


3SBIO (Shenyang Sunshine) »15/11/2007 [Company watch]
3SBio Inc. Q3 net far outgrows revenue

Chinese biotech company 3SBio Inc. ( SSRX.NASDAQ) posted 57.3 percent net revenue rise in the 3rd quarter from the same period of 2006 to 7.5 million U.S. dollars, according to its latest financial report issued on Tuesday....   more»


China Sky One Medical,Inc. »13/11/2007 [Company watch]
China Sky One Medical Reports Third Quarter 2007 Financial Results

3Q07 Revenue Up 148% to $16.8 Million ---- 3Q07 Net Income Up 195% to $5.4 Million HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial results for the three month and nine month periods ending September 30, 2007....   more»


Simcere Pharmaceutical Group »26/11/2007 [Company watch]
Simcere Acquires Nanjing Tung Chit

Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that it has acquired 100% of Master Luck Corporation Limited, which holds 85.7% of Nanjing Tung Chit Pharmaceutical Co., Ltd. ("Tung Chit"), for a total cash consideration of RMB32.6 million (US$4.4 million). Tung Chit is a fast-growing manufacturer and supplier of anti-cancer drugs in China. Its leading product is a nedaplatin injection, trademarked as Jiebaisu, a first-to-market platinum based chemotherapeutic drug approved for the treatment of a wide range of solid tumors, including head-and-neck cancer, small cell and non-small cell lung cancer and esophageal cancer. Since its launch, Jiebaisu has been used by a number of major Chinese hospitals, specializing in cancer treatment, in many provinces across China. According to the China Hospital Drug Information, Jiebaisu's share of the nedaplatin market in China was over 80 percent in 2006. Being a new generation, broad spectrum platinum based chemotherapeutic drug, nedaplatin is expected to have significant growth potential in China....   more»


China Aoxing Pharmaceutical Company, Inc. »26/11/2007 [Company watch]
China Aoxing Pharmaceutical Designated as a Key Manufacturer of Cancer Pain Drug by China SFDA

China Aoxing Pharmaceutical Company, Inc. , which has the largest manufacturing facility and product pipeline for highly regulated narcotic medicines and pain medication in China, today announced that the China State Food & Drug Administration (SFDA) granted the Company the designated manufacturer status to produce Tilidine Tablets and Capsules, a highly regulated narcotic drug, in order to address significant unmet medical needs in cancer pain management in China. Maybe a working partner?...   more»


Lotus Pharmaceuticals »17/01/2008 [Company watch]
Lotus Pharmaceuticals Inc. Retains CCG Elite

Lotus Pharmaceuticals, Inc. ("Lotus" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign...   more»


3SBIO (Shenyang Sunshine) »28/01/2008 [Company watch]
3Sbio appoints Kevin Sow Peng Teo CFO

Chinese biotech company 3Sbio has appointed of Kevin Teo as the Chief Financial Officer. A company release said Teo would be replacing Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008. Dr. Jing Lou, CEO of 3SBio, commented, "I am pleased to welcome Kevin Teo to 3SBio's senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin's ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors." Teo has over two decades experience working with various companies in a variety of positions. He was the Group Business Controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing and Beijing. Before East Asia Power, Teo held senior roles at Huawei Technologies Co. Ltd. (Shenzhen), Siemens Malaysia Sdn. Bhd., Siemens Cerberus Sdn. Bhd., Wetlands International - Asia Pacific, Chua Song Seng, and Anuarul Azizan Chew...   more»


China Biopharmaceuticals Holdings »29/01/2008 [Company watch]
China Pharma Holdings, Inc. (CPHI.OB) Receives Chinese SFDA Approval for Generic Bumetanide Injection

China Pharma Holdings, Inc. ("China Pharma") which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic Bumetanide injection which is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome by inducing dieresis...   more»


China Biopharmaceuticals Holdings »15/02/2008 [Company watch]
China Pharma Appoints Three Independent Non-Executive Directors

China Pharma Holdings, Inc. ("China Pharma") which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced the appointment of G. Michael Bennett, Yingwen Zhang and Baowen Dong to its Board of Directors, forming the Company's Audit Committee. G. Michael Bennett is Chairman of the Audit Committee. The Company also announced the resignation of Heung Mei Tsui as a member of the Company's Board of Directors, effective February 1, 2008, with no disagreements The appointment of Bennett, Zhang and Dong to China Pharma's board brings the total number of directors to five, and the total number of independent non-executive directors to three....   more»


China Aoxing Pharmaceutical Company, Inc. »13/03/2008 [Company watch]
China Aoxing Pharmaceutical to Acquire Shijiangzhuang Lerentang Pharmaceutical Co.,

China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. -Acquisition to Expand Company's Market Position and Portfolio in Pain Management- China Aoxing Pharmaceutical Company, Inc. which has the largest manufacturing facility and product pipeline for highly regulated narcotic medicines and pain medication in China, today announced that Hebei Aoxing Pharmaceutical Group Company, the subsidiary of China Aoxing Pharmaceutical Company, signed a definitive acquisition agreement to acquire Shijiazhuang Lerentang Pharmaceutical Company Ltd. ("LRT"). LRT is a pharmaceutical company organized under the laws of China specializing in the manufacturing and distribution of modernized Chinese traditional medicines, with a strong portfolio of pain management products. . developed a rich line of pain management drugs in pills, tablets, capsules, oral solutions and other formulations. LRT's best selling product is the Zhong Tong An Capsules, an effective pain medicine developed solely by LRT to relieve dental pain, sore throats and oral ulcers. Zhong Tong An Capsules accounted for approximately 50% of LRT's total revenue in 2007. LRT currently has 52 products listed in the first and second classes of the National Medical Insurance Program, and 101 products entered in the national OTC medicine book. In 2004, LRT passed GMP production certificates for all of its production lines. "We are excited to gain significant progress in the LRT transaction and believe this acquisition will further support our position as a leading, diversified pain management products company," commented Zhenjiang Yue, Chairman and CEO of China Aoxing. "With LRT's integration, we will execute a key part of our business strategy by acquiring an established brand, profitable business, and synergistic product portfolio with significant commercialization value. LRT has a number of high value pain management products,...   more»


Simcere Pharmaceutical Group »20/03/2008 [Company watch]
Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Sales appointments

Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the appointment of Mr. Mark Chen, Pei-Chi as Vice President of Marketing and the promotion of Baoxing Zha and Dasheng Sun as the Vice Presidents of Hospital Sales and Retail Sales respectively....   more»


3SBIO (Shenyang Sunshine) »23/03/2008 [Company watch]
3S Bio announce new appointment

3SBio Inc. (''3SBio'' or the ''Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio. Since joining 3SBio in June 2007, Dr. Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr. Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China....   more»


China Sky One Medical,Inc. »02/04/2008 [Company watch]
China Sky One Medical, Inc. announced its 2007 revenues

China Sky One Medical, Inc. announced its 2007 revenues climbed 148% to $49.3 million. The company’s net income came in at $15.3 million, which equals $1.15 per share fully diluted and a profit margin of 31%. The company makes and markets traditional Chinese Medicines, most of which are for external use. It also produces diagnostic products....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.